Literature DB >> 33179472

A prognostic index predicting survival in transformed Waldenström macroglobulinemia.

Eric Durot1, Lukshe Kanagaratnam2, Saurabh Zanwar3, Efstathios Kastritis4, Shirley D'Sa5, Ramon Garcia-Sanz6, Cécile Tomowiak7, Bénédicte Hivert8, Elise Toussaint9, Caroline Protin10, Jithma P Abeykoon3, Thomas Guerrero-Garcia11, Gilad Itchaki12, Josephine M Vos13, Anne-Sophie Michallet14, Sophie Godet15, Jehan Dupuis16, Stéphane Leprêtre17, Joshua Bomsztyk5, Pierre Morel18, Véronique Leblond19, Steven P Treon20, Meletios A Dimopoulos4, Prashant Kapoor3, Alain Delmer15, Jorge J Castillo20.   

Abstract

Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) usually associated with a poor prognosis. The objective of this study was to develop and validate a prognostic index for survival in transformed WM patients. Through this multicenter, international collaborative effort, we developed a scoring system based on data from 133 patients with transformed WM who were evaluated between 1995 and 2016 (training cohort). Univariate and multivariate analyses were used to propose a prognostic index with 2-year survival after transformation as an end-point. For external validation, a data set of 67 patients was used to evaluate the performance of the model (validation cohort). By multivariate analysis, three adverse covariates were identified as independent predictors of 2-year survival after transformation: elevated serum LDH (2 points), platelet count < 100 x 109/L (1 point) and any previous treatment for WM (1 point). Three risk groups were defined: low-risk (0-1 point, 24% of patients), intermediate-risk (2-3 points, 59%, hazard ratio (HR) = 3.4) and high-risk (4 points, 17%, HR = 7.5). Two-year survival rates were 81%, 47%, and 21%, respectively (P < 0.0001). This model appeared to be a better discriminant than the International Prognostic Index (IPI) and the revised IPI (R-IPI). We validated this model in an independent cohort. This easy-to-compute scoring index is a robust tool that may allow identification of groups of transformed WM patients with different outcomes and could be used for improving the development of risk-adapted treatment strategies.

Entities:  

Year:  2020        PMID: 33179472     DOI: 10.3324/haematol.2020.262899

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  2 in total

Review 1.  Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual.

Authors:  Morie A Gertz
Journal:  J Clin Oncol       Date:  2022-06-14       Impact factor: 50.717

Review 2.  Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.

Authors:  Saurabh Zanwar; Jithma P Abeykoon
Journal:  Ther Adv Hematol       Date:  2022-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.